Table 2 Clinical outcomes at 9 and 12 months following study enrollment
Outcome | All Patients | Biologic CTPs | Non-biologic CTPs |
|---|---|---|---|
9 months following study enrollment: | |||
 CID without current GC use (N (%)) | 30/53 (57%) | 27/47 (57%) | 3/6 (50%) |
 CID irrespective of current GC use (N (%)) | 32/53 (60%) | 29/47 (62%) | 3/6 (50%) |
 cJADAS-10 ≤ 1 + no fever without current GC use (N (%)) | 32/48 (67%) | 29/43 (67%) | 3/5 (60%) |
 cJADAS-10 ≤ 1 + no fever irrespective of current GC use (N (%)) | 34/48 (71%) | 31/43 (72%) | 3/5 (60%) |
 cJADAS-10 ≤ 2.5 + no fever without current GC use (N (%)) | 36/48 (75%) | 33/43 (77%) | 3/5 (60%) |
 cJADAS-10 ≤ 2.5 + no fever irrespective of current GC use (N (%)) | 38/48 (79%) | 35/43 (81%) | 3/5 (60%) |
 cJADAS-10 (mean (SD)) | 1.5 (3.3) | 1.3 (3.0) | 3.4 (5.6) |
 cJADAS-10 (median (IQR)) | 0 (0, 1.0) | 0 (0, 1.0) | 0 (0, 4.0) |
12 months following study enrollment: | |||
 CID without current GC use (N (%)) | 31/55 (56%) | 28/49 (57%) | 3/6 (50%) |
 CID irrespective of current GC use (N (%)) | 34/55 (62%) | 30/49 (61%) | 4/6 (67%) |
 cJADAS-10 ≤ 1 + no fever without current GC use (N (%)) | 33/47 (70%) | 31/42 (74%) | 2/5 (40%) |
 cJADAS-10 ≤ 1 + no fever irrespective of current GC use (N (%)) | 35/45 (78%) | 32/40 (80%) | 3/5 (60%) |
 cJADAS-10 ≤ 2.5 + no fever without current GC use (N (%)) | 36/47 (77%) | 33/42 (79%) | 3/5 (60%) |
 cJADAS-10 ≤ 2.5 + no fever irrespective of current GC use (N (%)) | 38/45 (84%) | 34/40 (85%) | 4/5 (80%) |
 cJADAS-10 (mean (SD)) | 2.0 (5.7) | 1.7 (5.4) | 4.0 (7.9) |
 cJADAS-10 (median (IQR)) | 0 (0, 0.5) | 0 (0, 0.5) | 0 (0, 2.0) |